2008-07-02 16:13:16 - www.companiesandmarkets.com adds new report - Premium Company Profile - Human Genome Sciences

www.companiesandmarkets.com/Summary-Company-Profile/Premium-Comp ..
Introduction

HGS has a broad portfolio of product candidates which are under clinical development for use in large therapeutic categories including immunology, infectious disease and oncology.



The company has three products advancing into late-stage clinical development: Albuferon for chronic hepatitis C, Lymphostat-B for systemic lupus erythematosus, and Abthraxtm for anthrax disease.



The company’s biggest contributor to sales growth

out to 2010 continues to be revenues from R&D contracts. Revenues from R&D contracts are expected to increase at a CAGR of 61%, from $26 million in 2006 to $172 million in 2010. Revenue from product sales includes, Albuferon and LymphoStat- B which is expected to be launched in 2010.



Scope

Access all the important information and analysis on a company in a single report
Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company’s adjusted five year financial data along with key ratios and market capitalization


Highlights



Reasons to Purchase